PARP-1 Regulates Resistance of Pancreatic Cancer to TRAIL Therapy

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-13-0516
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

A PARP Inhibitor in Pancreatic Cancer: Enhancement Anti-Tumour Activity of Chemoradiation Therapy Against Pancreatic Cancer?

EBioMedicine
BiochemistryMedicineGeneticsMolecular Biology
2019English

SKP2 Confers Resistance of Pancreatic Cancer Cells Towards TRAIL-induced Apoptosis

International Journal of Oncology
Cancer ResearchOncology
2010English

F-Box Protein-Mediated Resistance to PARP Inhibitor Therapy

Molecular Cell
Cell BiologyMolecular Biology
2019English

Soluble TRAIL Armed Human MSC as Gene Therapy for Pancreatic Cancer

Scientific Reports
Multidisciplinary
2019English

Correction: Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors With Three Different Drug Combinations

PLoS ONE
Multidisciplinary
2016English

Hsulf-1 Regulates Growth and Invasion of Pancreatic Cancer Cells

Journal of Clinical Pathology
MedicineForensic MedicinePathology
2006English

Sirtuin-1 Regulates Acinar-To-Ductal Metaplasia and Supports Cancer Cell Viability in Pancreatic Cancer

Cancer Research
Cancer ResearchOncology
2013English

C-Rel Is a Critical Mediator of NF-κB-dependent TRAIL Resistance of Pancreatic Cancer Cells

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2014English

Triptolide Sensitizes Pancreatic Cancer Cells to TRAIL-induced Activation of the Death Receptor Pathway

Cancer Letters
Cancer ResearchOncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy